G

Genomed SA
WSE:GEN

Watchlist Manager
Genomed SA
WSE:GEN
Watchlist
Price: 26.2 PLN Market Closed
Market Cap: 34.6m PLN
Have any thoughts about
Genomed SA?
Write Note

Relative Value

The Relative Value of one GEN stock under the Base Case scenario is 40.05 PLN. Compared to the current market price of 26.2 PLN, Genomed SA is Undervalued by 35%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

GEN Relative Value
Base Case
40.05 PLN
Undervaluation 35%
Relative Value
Price
G
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
76
vs Industry
82
Median 3Y
2.2
Median 5Y
2.3
Industry
8.1
vs History
53
vs Industry
3
Median 3Y
65.6
Median 5Y
66
Industry
23
vs History
47
vs Industry
6
Median 3Y
30.1
Median 5Y
29
Industry
23.4
vs History
vs Industry
7
Median 3Y
22
Median 5Y
22
Industry
27.3
vs History
82
vs Industry
23
Median 3Y
5.3
Median 5Y
5.4
Industry
2.6
vs History
73
vs Industry
73
Median 3Y
2.1
Median 5Y
2.1
Industry
8.1
vs History
74
vs Industry
61
Median 3Y
5.3
Median 5Y
5.4
Industry
9.6
vs History
57
vs Industry
6
Median 3Y
26.8
Median 5Y
26.8
Industry
4.3
vs History
63
vs Industry
3
Median 3Y
47.9
Median 5Y
56.8
Industry
3.8
vs History
47
vs Industry
6
Median 3Y
27.9
Median 5Y
26.8
Industry
6
vs History
vs Industry
8
Median 3Y
23.8
Median 5Y
23.8
Industry
3.8
vs History
92
vs Industry
33
Median 3Y
6.8
Median 5Y
7.1
Industry
4.8

Multiples Across Competitors

GEN Competitors Multiples
Genomed SA Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
PL
Genomed SA
WSE:GEN
34.6m PLN 1.6 58.8 20.9 34.8
FR
Pharnext SCA
OTC:PNEXF
6T USD 37 678 545.3 -179 080.5 -217 460.8 -214 979.3
US
Abbvie Inc
NYSE:ABBV
299.8B USD 5.4 59 14.8 22.7
US
Amgen Inc
NASDAQ:AMGN
159.1B USD 4.9 37.6 17.5 33.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
124.7B USD 11.7 -259.9 26.3 27.6
US
Gilead Sciences Inc
NASDAQ:GILD
114.8B USD 4.1 910.9 10.1 10.1
US
Epizyme Inc
F:EPE
94.1B EUR 1 869.7 -477.1 -519.6 -505.7
AU
CSL Ltd
ASX:CSL
137.3B AUD 6 33.5 20.7 25.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
86.2B USD 6.2 18.5 17 18.9
US
Seagen Inc
F:SGT
39.3B EUR 18 -55.2 -59.4 -53.6
NL
argenx SE
XBRU:ARGX
34B EUR 18.4 -129.2 -103.9 -75.7
P/E Multiple
Earnings Growth
PL
G
Genomed SA
WSE:GEN
Average P/E: 186.4
58.8
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -179 080.5 N/A
US
Abbvie Inc
NYSE:ABBV
59
412%
US
Amgen Inc
NASDAQ:AMGN
37.6
73%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -259.9
42%
US
Gilead Sciences Inc
NASDAQ:GILD
910.9
75%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -477.1 N/A
AU
CSL Ltd
ASX:CSL
33.5
65%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.5
43%
US
S
Seagen Inc
F:SGT
Negative Multiple: -55.2 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -129.2 N/A
EV/EBITDA Multiple
EBITDA Growth
PL
G
Genomed SA
WSE:GEN
Average EV/EBITDA: 18.2
20.9
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -217 460.8 N/A
US
Abbvie Inc
NYSE:ABBV
14.8
28%
US
Amgen Inc
NASDAQ:AMGN
17.5
63%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.3
38%
US
Gilead Sciences Inc
NASDAQ:GILD
10.1
12%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -519.6 N/A
AU
CSL Ltd
ASX:CSL
20.7
42%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17
46%
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.4 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -103.9 N/A
EV/EBIT Multiple
EBIT Growth
PL
G
Genomed SA
WSE:GEN
Average EV/EBIT: 24.7
34.8
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -214 979.3 N/A
US
Abbvie Inc
NYSE:ABBV
22.7
88%
US
Amgen Inc
NASDAQ:AMGN
33.2
93%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
27.6
44%
US
Gilead Sciences Inc
NASDAQ:GILD
10.1
29%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -505.7 N/A
AU
CSL Ltd
ASX:CSL
25.8
55%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.9
54%
US
S
Seagen Inc
F:SGT
Negative Multiple: -53.6 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -75.7 N/A

See Also

Discover More
Back to Top